Key Points
- Director Leslie Norwalk sold 5,000 NBIX shares on December 15 at an average price of $152.23 for total proceeds of $761,150, cutting her stake by 40.23% to 7,429 shares (≈$1.13M).
- Neurocrine beat expectations in its latest quarter with EPS of $2.17 vs. $1.58 consensus and revenue of $794.9M, up 27.8% year-over-year.
- The stock trades around $142.51 with a $14.21B market cap and a consensus analyst rating of "Moderate Buy" and average price target of about $174.76 (broker targets range roughly $164–$195).
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Leslie Norwalk sold 1,190 shares of the business's stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $155.09, for a total value of $184,557.10. Following the completion of the transaction, the director directly owned 6,239 shares in the company, valued at approximately $967,606.51. This represents a 16.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Neurocrine Biosciences Price Performance
Shares of NASDAQ:NBIX traded up $0.43 during midday trading on Thursday, reaching $142.13. The company's stock had a trading volume of 90,156 shares, compared to its average volume of 1,147,969. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $160.18. The company has a market capitalization of $14.17 billion, a P/E ratio of 34.01, a P/E/G ratio of 0.98 and a beta of 0.27. The business's fifty day simple moving average is $145.93 and its 200-day simple moving average is $137.76.
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.59. The business had revenue of $794.90 million for the quarter, compared to the consensus estimate of $746.61 million. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The firm's quarterly revenue was up 27.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.81 EPS. On average, analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
NBIX has been the topic of several research analyst reports. Wedbush reissued an "outperform" rating on shares of Neurocrine Biosciences in a research note on Monday, September 22nd. JPMorgan Chase & Co. increased their price objective on Neurocrine Biosciences from $171.00 to $179.00 and gave the company an "overweight" rating in a research report on Monday, November 3rd. Needham & Company LLC lifted their target price on Neurocrine Biosciences from $170.00 to $184.00 and gave the company a "buy" rating in a research note on Wednesday, October 29th. Piper Sandler boosted their target price on Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 29th. Finally, UBS Group upped their price target on Neurocrine Biosciences from $188.00 to $195.00 and gave the company a "buy" rating in a research note on Thursday, October 9th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of "Moderate Buy" and an average target price of $174.76.
Read Our Latest Report on NBIX
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in NBIX. Tudor Investment Corp ET AL grew its stake in shares of Neurocrine Biosciences by 805.3% during the third quarter. Tudor Investment Corp ET AL now owns 26,860 shares of the company's stock worth $3,771,000 after purchasing an additional 23,893 shares during the period. Allworth Financial LP boosted its holdings in Neurocrine Biosciences by 68.1% during the third quarter. Allworth Financial LP now owns 5,009 shares of the company's stock worth $703,000 after buying an additional 2,029 shares during the last quarter. IFP Advisors Inc boosted its holdings in Neurocrine Biosciences by 14.0% during the third quarter. IFP Advisors Inc now owns 2,475 shares of the company's stock worth $347,000 after buying an additional 303 shares during the last quarter. Swiss Life Asset Management Ltd grew its position in shares of Neurocrine Biosciences by 31.9% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 17,767 shares of the company's stock worth $2,494,000 after buying an additional 4,293 shares during the period. Finally, CIBC Private Wealth Group LLC increased its stake in shares of Neurocrine Biosciences by 17,250.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 7,981 shares of the company's stock valued at $1,120,000 after acquiring an additional 7,935 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.
Neurocrine Biosciences Company Profile
(
Get Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
